RxDoctor Payments Data

Safwat Shaker

Internal Medicine · Hackensack, NJNPI 1144246042

Payments from drug & device makers

$7,573in general payments, 2019–2025

Across 480 payments — averaging $15.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Amgen$1K
  • AstraZeneca$847
  • GSK$481
  • Abbott$436
  • Lilly USA, LLC$296
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$7,47999%
  • Education$941%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,573 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$205,856
Medicare patients
277
Services billed
2,538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide87$125,789
EliquisApixaban177$119,664
FarxigaDapagliflozin Propanediol58$75,517
JardianceEmpagliflozin43$54,798
ProliaDenosumab32$53,881
MounjaroTirzepatide33$42,969
JanuviaSitagliptin Phosphate27$42,446
JanumetSitagliptin Phos/Metformin Hcl37$36,563
RybelsusSemaglutide13$32,075
LinzessLinaclotide25$22,704
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$21,761
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$20,242
XareltoRivaroxaban15$15,184
MyrbetriqMirabegron31$13,743
Breo ElliptaFluticasone/Vilanterol20$10,028

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,819$157,863100 claims
PfizerEliquis$145$119,664177 claims
AstraZenecaFarxiga, Breztri Aerosphere$847$95,75990 claims
MerckJanuvia, Janumet$54$79,00964 claims
Boehringer IngelheimJardiance, Spiriva Respimat$42$60,50554 claims
AmgenProlia$1,096$53,88132 claims
Lilly USA, LLCMounjaro$296$42,96933 claims
GSKTrelegy Ellipta, Breo Ellipta$481$31,79052 claims
AbbVieLinzess$159$22,70425 claims
Johnson & JohnsonXarelto$174$15,18415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Hackensack

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →